C3 Reduct ODN
C3 Reduct ODN
C3® Reduct: 'the power of curcumin reductive metabolites' - Tetrahydrocurcuminoid: the directly active form of turmeric
C3® Reduct allows to use the active form of turmeric curcuminoids, and move away from the myth of bioavailability. Colorless and highly stable, suitable for gummies, gels, bars, tablets, premixes etc…
Curcuminoids exert their effects through gastrointestinal as well as systemic routes. They are metabolized to Tetrahydrocurcuminoids (THCs), depending also on their bio-availability. Many ‘improved’ curcuma extracts include new technologies, new process or formulations with chemical, said to “improve the bio availability”, in the serum and sometimes to the detriment of the real bio-active forms. Besides, there’s the challenge to be considered as novel foods since they have been developed after may 1997.
C3® Reduct overcomes the bioavailability limitation of the parent curcuminoids in the most functional way since directly providing the active metabolite. Research has shown that C3® Reduct is a remarkable antioxidant, superior even to curcumin itself in this respect. The beneficial impact of THCs on colonic health also has received strong scientific reports. THCs are also an excellent anti-inflammatory agent.
C3® Reduct, which so contains directly the curcuminoid metabolites - THCs - has obtained Novel Food approval from the EFSA (end 12/2021), daily dose up to 140mg. This may well be the first time a metabolite of a nutrient has been approved as a Novel Food.
It’s a Creamy-white crystalline powder (cf. easier cleaning of equipment), with a total content of 95% THCs, the hydrogenated derivatives of yellow curcuminoids (mainly curcumin, demethoxycurcumin, and bisdemethoxycurcumin) from the rhizomes of turmeric.
Regular studies are performed with tetrahydrocyurcuminoids (last on november 2020: Efficacy for the Treatment of Canker Sore and Gingivitis).
In cosmetic, it brings a strong skin whitening, is found to have anti-inflammatory, antioxidant and tyrosinase inhibitory effects. Also against mycosis on skin, hair and nails (antifungal) - see our TetraPure.
Curcuma - Free curcumins, 3 peaks, anti-inflammatory, antioxidant, digestion ...
Curcuma longa is a plant of the ginger family that has been used for centuries in Asia, also known as Indian saffron, it is among the oldest natural medications in the world. Indeed, the rhizome of this perennial plant has been used for thousands of years in traditional Chinese and Ayurvedic medicine.
In China, its rhizomes were dried and powdered to be used to soothe pain and treat congestion. In Ayurvedic medicine, curcuma was immediately appreciated for its anti-inflammatory and antioxidant properties. It can even be seen in the Atharva-Veda - a sacred text of Hinduism - around the 4th century. It is referred to there as "Hrudroga", meaning a remedy useful in the treatment of heart problems.
Many properties are recognized for curcuma: anti-inflammatory, helps digestion, IBD, regulator of blood sugar (type 2 diabetes), hepatoprotector, anti-cancer ...
The curcuma rhizome contains a set of substances, curcuminoids, of which curcumin is the most abundant. Chemically, these substances have marked antioxidant properties, as well as anti-inflammatory properties. In addition, curcumin has shown, in cell cultures, an ability to block the multiplication of several types of cancer cells. Curcuminoids are metabolized in the body, especially to tetrahydrocurcuminoids.
Tetrahydrocurcuminoids for the Treatment of Canker Sore and Gingivitis
Overall, the findings of this study show that supplementation of THCs for 21 days reduced the pain and prevented the progression of the disease in patients suffering from canker sore and gingivitis without adverse side effects.
Canker sore (Recurrent Apthous Stomatitis, RAS) or the painful ulcers onside the mouth or at the base of the gums, and gingivitis, the common gum disease associated with gum bleeding, are among the common oral health care issues afflicting the population today, yet treatment regimens currently available leave much room for improvement. In a recent clinical trial involving 30 canker sore patients and 29 patients with gingivitis, treatment with Curcumin C3 Reduct (two 100 mg chewable tablets/day) over a three week period showed remarkable results. At the end of the study, all canker sore patients were completely cured of their painful ulcerous lesions. The efficacy of C3 Reduct in gingivitis was evaluated by several parameters including gingival index score, bleeding and inflammation. C3 Reduct treatment led to excellent abatement of pain, numbness, ulcer formation, dryness with no staining or allergic symptoms. The results are published as a peer-reviewed paper in Evidenced-Based Complementary and Alternative Medicine: "Efficacy and Safety of Tetrahydrocurcuminoids for the treatment of Canker Sore and Gingivitis".
Background. Tetrahydrocurcuminoids (THCs) are among the major metabolites of curcuminoids with a higher bioavailability and physiological stability and exhibit a broad spectrum of therapeutic activities. )e objective of this study was to evaluate the efficacy of THCs in patients suffering from canker sore and gingivitis designed as an exploratory clinical trial.
Methods. This is an open label prospective pilot clinical trial carried out at two clinical centers: Noble Hospital, Pune, Maharashtra, and Sri Venkateshwara Hospital, Bangalore, Karnataka in India.
Participants were assigned to 21 days of treatment with chewable oral THCs supplement. Patients were instructed to self-administer one chewable tablet containing 100 mg of THCs twice daily for up to 21 days. )is clinical trial was registered at a public Clinical Trial Registry in India (http://www.ctri.nic.in). )irty-one canker sore and twentynine gingivitis patients participated in this study. Body mass index, throat numbness/relief, Visual Analog Scale (VAS) pain score, canker sore lesions, gingival appearance, inflammation and bleeding were assessed before and after treatment, at 14 and 21 days. Vital signs and laboratory parameters were assessed for safety.
Results. THCs treatment significantly reduced the reddening at the site, difficulty in chewing, swallowing, and VAS pain score in the canker sore patients. Further, both single and multiple lesions were completely healed. In gingivitis patients, gingival appearance, bleeding, and inflammation were significantly reduced. No adverse effects were observed during the study.
Conclusion. Overall, the findings of this study show that supplementation of THCs for 21 days reduced the pain and prevented the progression of the disease in patients suffering from canker sore and gingivitis without adverse side effects.
Efficacy and Safety of Tetrahydrocurcuminoids for the Treatment of Canker Sore and Gingivitis, Muhammed Majeed, Shaheen Majeed, and Kalyanam Nagabhushanam, Evidence-Based Complementary and Alternative Medicine, Volume 2020, Article ID 6611877, 10 pages
Currying skin health with multifunctional curcuminoids
This article discusses innovative applications of the natural compositions of Curcuminoids and Tetrahydrocurcuminoids, as well as a single component Tetrahydrocurcumin for skin ageing, antioxidants, etc...
Anstracts : The healthful spice turmeric, has traditionally been used in skin care since ancient times in South Asia. Recent scientific research has validated its inherent beneficial effects, both nutritional and topical.
Technological innovation in ingredients enables imparting the goodness of curcuminoids from "curry", (turmeric) into skin, hair and nails without being hampered by the yellow color. Tetrahydrocurcuminoids (a) are patented colorless derivatives of the yellow "bioprotectant" curcuminoids (b) with multifaceted benefits in anti-aging and skin protectant compositions. This article discusses innovative applications of the natural compositions of Curcuminoids and Tetrahydrocurcuminoids, as well as a single component Tetrahydrocurcumin.
Skin ageing and antioxidants : Aging is attributed to the effects of collective damage to connective tissues, that overpowers the body's natural ability to repair them. The perceptible signs of skin aging include discoloration, wrinkles, and texture loss. These effects result from structural and metabolic changes effected by biochemical reactions in the connective tissues, that are accelerated by free radicals. Environmental agents such as UV rays exacerbate the effects of free radical reactions and oxidative stress. These reactions to time and the environment are rooted in the metabolic processes in the body, and the ability of the internal machinery to combat stress and adapt to the environment (1, 2).
About 25 percent of the lipids in the skin surface are unsaturated, and therefore more prone to attack by free radicals... (to be continued)
Currying skin health with multifunctional curcuminoids - Household and Personal Care Today nr. 4/2007, Muhammed Majeed, Lakshmi Prakash. Curcuminoids and Tetra hydro curcuminoids (colorless hydrogenated
derivative of the natural yellow curcuminoids)
Efficacy and safety of tetrahydrocurcuminoid in the treatment of oral leukoplakia
C3 Reduct has been evaluated for for the treatment of Canker Sore and Gingivitis (oral care). A previously published independent clinical paper focused on the utility of C3 Reduct in oral leukoplakia which could ultimately progress to oral cancer in certain cases. C3 Reduct was applied as a 2% gel formulation in the affected areas inside the mouth.
The efficacy of C3 Reduct in gingivitis was evaluated by several parameters including gingival index score, bleeding and inflammation. C3 Reduct treatment led to excellent abatement of pain, numbness, ulcer formation, dryness with no staining or allergic symptoms. The results are published as a peer-reviewed paper in Evidenced-Based Complementary and Alternative Medicine: "Efficacy and Safety of Tetrahydrocurcuminoids for the treatment of Canker Sore and Gingivitis" authored by Dr. Muhammed Majeed, Shaheen Majeed, and Dr. Kalyanam Nagabhushanam (Volume 2020, Article ID 6611877).
A previously published independent clinical paper focused on the utility of C3 Reduct in oral leukoplakia which could ultimately progress to oral cancer in certain cases. C3 Reduct was applied as a 2% gel formulation in the affected areas inside the mouth. The researchers concluded that the topically applied gel was extremely effective in alleviating clinical symptoms. Remarkable histological improvement was seen in a subset of patients encouraging future long- term trials. The results, "Efficacy and Safety of Tetrahydrocurcuminoids in the Treatment of Oral Leukoplakia: A Pilot Study" by Yogesh Chhaparwal et al was published in Asian Journal of Pharmaceutical Clinical Research (Vol 11 Issue 12).
Objective: The objective of this study is to evaluate the efficacy and safety of tetrahydrocurcuminoid (THC) in the treatment of oral leukoplakia.Methods: Patients with oral mucosal lesions with clinical features of leukoplakia were selected, and an incisional biopsy of the lesion was performed to confirm the diagnosis. Demographic data, habit history, and complete medical history were documented. Subjects were given 2% THC gel (Sami Labs, Bengaluru) with advice to apply the gel to the affected areas, 5 times daily for 12 weeks. The lesion was examined, and its characteristics were documented in a standard manner at baseline, 3, 6, 9, and 12 weeks.
Results: Of the eight patients, 6 were males with age range from 40 to 70 years (mean age of 56 years). All the patients reported a reduction of burning sensation within 3 weeks of starting treatment and were completely asymptomatic by the end of the study. There was a decrease in the size of the lesion during the follow-up period. Reduction in thickness of the lesion was found in six of eight patients. Histological improvement a stage better was seen in three patients after completion of treatment. However, there was no histological improvement in four patients, and one patient progressed to mild dysplasia from hyperkeratosis without dysplasia.
Conclusion: THD when topically applied in gel form is remarkably effective in alleviating clinical symptoms. The remarkable histological improvement was seen in 3 of 8 patients.
Keywords: Curcumin, Leukoplakia, Efficacy, Oral care
Efficacy and safety of tetrahydrocurcuminoid in the treatment of oral leukoplakia: a pilot study, Yogesh Chhaparwal, Keerthilatha M Pai, M.S. Kamath, Sunitha Carnelio, Shubha Chhaparwal, Asian J Pharm Clin Res, Vol 11, Issue 12, 2018, 194-196
Safety of tetrahydrocurcuminoids from turmeric (Curcuma longa L.) as a novel food
22/12/2021 ; C3 Reduct is approved as a novel food - The Panel concludes that the NF, tetrahydrocurcuminoids from turmeric (C. longa L.), is safe for the target population at 140 mg/da (ie. 2 mg/kg bw per day)
Abstract Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on tetrahydrocurcuminoids from turmeric (Curcuma longa L.) as a novel food (NF) pursuant to Regulation (EU) 2015/2283. Tetrahydrocurcuminoids are derivatives of curcuminoids, produced chemically by hydrogenation of curcuminoids extracted from the rhizomes of C. longa L. The NF consists of more than 95% of tetrahydrocurcuminoids. The applicant proposed to use the NF in food supplements at a maximum dose of 300 mg/day for adults excluding pregnant and lactating women. Taking into account the composition of the NF and the proposed conditions of use, consumption of the NF is not nutritionally disadvantageous. There are no concerns regarding genotoxicity of the NF. Based on a 90-day oral toxicity study and a reproduction/developmental toxicity screening test performed with the NF, the Panel derives a safe level of 2 mg/kg body weight per day. For the target population this level corresponds to 140 mg/day, which is lower than the use level as proposed by the applicant. The Panel concludes that the NF, tetrahydrocurcuminoids from turmeric (C. longa L.), is safe for the target population at 140 mg/day
Note : an other onternal study on the safety/toxicological profile of THC
● Acute oral toxicity LD50: >500 mg/kg body weight
● Acute dermal toxicity LD50: >2000 mg/kg body weight
● Primary skin irritation test: Did not cause any irritation
● Mucous membrane irritation test: Did not cause any irritation
● AMES test: Non-mutagenic
20 healthy human volunteers and orally administered 300 mg of THC once daily for 28 days. Laboratory parameters analyzed at the baseline and at end of the study showed no significant difference in hematological parameters such as leukocyte count, erythrocyte count, hemoglobin, hematocrit, platelets etc. There was no significant change in body mass index (BMI) and adverse effects observed during the study.
Keywords: novel foods, tetrahydrocurcuminoids, Curcuma longa L., turmeric, food supplement, safety
Safety of tetrahydrocurcuminoids from turmeric (Curcuma longa L.) as a novel food pursuant to Regulation (EU) 2015/2283 - EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA)
Bioavailability, Absorption and Metabolism of Curcumin
How curcumin should be delivered in vivo, how bioavailable is it, how well curcumin is absorbed and how it is metabolized, is the focus of this review. Various formulations of curcumin that are currently available are also discussed as various curcumin-based products include capsules, tablets, ointments, energy drinks, soaps, and cosmetics
Curcumin (diferuloylmethane) is a yellow pigment present in the spice turmeric (Curcuma longa) that has been associated with antioxidant, anti-inflammatory, anticancer, antiviral, and antibacterial activities as indicated by over 6,000 citations. In addition, over one hundred clinical studies have been carried out with curcumin. One of the major problems with curcumin is perceived to be the bioavailability. How curcumin should be delivered in vivo, how bioavailable is it, how well curcumin is absorbed and how it is metabolized, is the focus of this review. Various formulations of curcumin that are currently available are also discussed.
Curcumin / Piperine : Besides these natural compounds have been also used to increase the bioavailability of curcumin. One of them is piperine, a major component of black pepper, known as inhibitor of hepatic and intestinal glucuronidation and is also shown to increase the bioavailability of curcumin. This effect of piperine on the pharmacokinetics of curcumin has been shown to be much greater in humans than in rats. In humans, curcumin bioavailability was increased by 2,000% at 45 minutes after co-administering curcumin orally with piperine, whereas in rats, it has been found that concomitant administration of piperine 20 mg/kg with curcumin 2 g/kg increased the serum concentration of curcumin by 154% for a short period of 1-2 hours post drug. The study shows that in the dosages used, piperine enhances the serum concentration, extent of absorption and bioavailability of curcumin in both rats and humans with no adverse effects
Key words : Curcumin, Nano-formulation, Biological availability, Metabolism, Anticancer
Recent Developments in Delivery, Bioavailability, Absorption and Metabolism of Curcumin: the Golden Pigment from Golden Spice, Cancer Res Treat. 2014;46(1): 2-18
Curcumin and piperine supplementation of obese mice under caloric restriction
Conclusions : It is plausible that supplementing the high fat diet of CR mice with Cur + Pip may increase loss of body fat and suppresses HFD induced inflammation. Combination of Cur and Pip has potential to enhance CR effects for the prevention of metabolic syndrome.
Background : Dietary bioactive compounds capable of improving metabolic profiles would be of great value, especially for overweight individuals undergoing a caloric restriction (CR) regimen. Curcumin (Cur), a possible anti-obesity compound, and piperine (Pip), a plausible enhancer of Cur’s bioavailability and efficacy, may be candidate agents for controlling body fat, metabolism and low grade inflammation.
Methods : 47 eight-week-old male C57BL/6 mice were fed a high fat diet (HFD) for 23 weeks to induce obesity. Then, mice were divided into 5 groups. Group 1 continued on HFD ad libitum. The other 4 groups underwent CR (reduced 10% HFD intake for 10 weeks, 20% for 20 weeks) with Cur, Pip, Cur + Pip or none of these. Percent body fat, plasma inflammatory markers associated with obesity (interferon (IFN)-γ, interleukin (IL)-10, IL-12 p70, IL-1β, IL-6 and KC/GRO), plasma Cur metabolites and liver telomere length were measured.
Results : Compared to the other groups, obese mice who underwent CR and received Cur + Pip in their diet lost more fat and had significantly lower IL-1β and KC/GRO. Tandem mass spectrometry analysis of plasma from obese mice under CR showed no difference in Cur metabolite levels between groups supplemented with Cur alone or combined with Pip. However, plasma IL-1β levels were inversely correlated with curcumin glucuronide. Minor modulation of telomere length were observed.
Conclusions : It is plausible that supplementing the high fat diet of CR mice with Cur + Pip may increase loss of body fat and suppresses HFD induced inflammation. Combination of Cur and Pip has potential to enhance CR effects for the prevention of metabolic syndrome.
Curcumin and piperine supplementation of obese mice under caloric restriction modulates body fat and interleukin - Nutrition Metabolism - Taiki Miyazawa, Kiyotaka Nakagawa, Sharon H. Kim, Michael J. Thomas, Ligi Paul, Jean-Marc Zingg, Gregory G. Dolnikowski, Susan B. Roberts, Fumiko Kimura, Teruo Miyazawa, Angelo Azzi and Mohsen Meydani - Miyazawa et al. Nutrition & Metabolism (2018) 15:12
Curcumin boosts DHA in the brain
The n-3 fatty acids DHA and EPA are essential for human health that are obtained through dietary animal sources or synthesized from precursors. We provide evidence that curcumin enhances the biosynthesis of hepatic DHA from n-3 precursors and enhances DHA accretion in the brain. These data provide a novel insight into a potential mechanism by which curcumin ameliorates neurocognitive disease.
Dietary deficiency of docosahexaenoic acid (C22: 6n-3; DHA) is linked to the neuropathology of several cognitive disorders, including anxiety. DHA, which is essential for brain development and protection, is primarily obtained through the diet or synthesized from dietary precursors, however the conversion efficiency is low. Curcumin (diferuloylmethane), which is a principal component of the spice turmeric, complements the action of DHA in the brain, and this study was performed to determine molecular mechanisms involved. We report that curcumin enhances the synthesis of DHA from its precursor, α-linolenic acid (C18: 3n-3; ALA) and elevates levels of enzymes involved in the synthesis of DHA such as FADS2 and elongase 2 in both liver and brain tissue. Furthermore, in vivo treatment with curcumin and ALA reduced anxiety-like behavior in rodents. Taken together, these data suggest that curcumin enhances DHA synthesis, resulting in elevated brain DHA content. These findings have important implications for human health and the prevention of cognitive disease, particularly for populations eating a plant-based diet or who do not consume fish, a primary source of DHA, since DHA is essential for brain function and its deficiency is implicated in many types of neurological disorders.
Conclusion : The n-3 fatty acids DHA and EPA are essential for human health that are obtained through dietary animal sources or synthesized from precursors. We provide evidence that curcumin enhances the biosynthesis of hepatic DHA from n-3 precursors and enhances DHA accretion in the brain. These data provide a novel insight into a potential mechanism by which curcumin ameliorates neurocognitive disease.
Keywords : DHA synthesis; Curcumin; ALA; DPA; omega 3 fatty acids; docosahexaenoic acid
Curcumin boosts DHA in the brain: implications for the prevention of anxiety disorders, Biochim Biophys Acta. 2015 May ; 1852(5): 951–961. doi:10.1016/ j.bbadis. 2014.12.005, Aiguo Wu, Emily E. Noble, Ethika Tyagi, Zhe Ying, Yumei Zhuang
Curcumin and Diabetes: A Systematic Review
Here, we review the recent literature on the applications of curcumin for glycemia and diabetes-related liver disorders, adipocyte dysfunction, neuropathy, nephropathy, vascular diseases, pancreatic disorders, and other complications, and we also discuss its antioxidant and anti-inflammatory properties.
Abstract : Turmeric (Curcuma longa), a rhizomatous herbaceous perennial plant of the ginger family, has been used for the treatment of diabetes in Ayurvedic and traditional Chinese medicine. The active component of turmeric, curcumin, has caught attention as a potential treatment for diabetes and its complications primarily because it is a relatively safe and inexpensive drug that reduces glycemia and hyperlipidemia in rodent models of diabetes. Here, we review the recent literature on the applications of curcumin for glycemia and diabetes-related liver disorders, adipocyte dysfunction, neuropathy, nephropathy, vascular diseases, pancreatic disorders, and other complications, and we also discuss its antioxidant and anti-inflammatory properties. The applications of additional curcuminoid compounds for diabetes prevention and treatment are also included in this paper. Finally, we mention the approaches that are currently being sought to generate a “super curcumin” through improvement of the bioavailability to bring this promising natural product to the forefront of diabetes therapeutics.
Conclusion : Recent research has provided the scientific basis for “traditional” curcumin and confirmed the important role of curcumin in the prevention and treatment of diabetes and its associated disorders. Curcumin could favorably affect most of the leading aspects of diabetes, including insulin resistance, hyperglycemia, hyperlipidemia, and islet apoptosis and necrosis (Figure 2). In addition, curcumin could prevent the deleterious complications of diabetes. Despite the potential tremendous benefits of this multifaceted nature product, results from clinical trials of curcumin are only available in using curcumin to treat diabetic nephropathy, microangiopathy and retinopathy so far. Studies are badly needed to be done in humans to confirm the potential of curcumin in limitation of diabetes and other associated disorders. Further, multiple approaches are also needed to overcome limited solubility and poor bioavailability of curcumin. These include synthesis of curcuminoids and development of novel formulations of curcumin, such as nanoparticles, liposomal encapsulation, emulsions, and sustained released tablets. Enhanced bioavailability and convinced clinical trial results of curcumin are likely to bring this promising natural product to the forefront of therapeutic agents for diabetes by generating a “super curcumin” in the near future.
Curcumin and Diabetes: A Systematic Review, Dong-wei Zhang, Min Fu, Si-Hua Gao, and Jun-Li Liu, Evidence-Based Complementary and Alternative Medicine Volume 2013, Article ID 636053, 16 pages
Curcumin inhibits Zika and chikungunya virus
These results expand the family of viruses sensitive to curcumin and provide a mechanism of action for curcumin's effect on these enveloped viruses. The ability of curcumin to prevent viral replication strongly suggests that this molecule and its derivatives may hold promise for the development of broad-range antivirals. Curcumin in the human diet, further, could provide a simple means to prevent infection by enveloped viruses.
Several compounds extracted from spices and herbs exhibit antiviral effects in vitro, suggesting potential pharmacological uses. Curcumin, a component of turmeric, has been used as a food additive and herbal supplement due to its potential medicinal properties. Previously, curcumin exhibited antiviral properties against several viruses, including dengue virus and hepatitis C virus, among others. Here, we describe the antiviral effect of curcumin on Zika and chikungunya viruses, two mosquito-borne outbreak viruses. Both viruses responded to treatment of cells with up to 5 mM curumin without impacting cellular viability.We observed that direct treatment of virus with curcumin reduced infectivity of virus in a dose- and timedependent manner for these enveloped viruses, as well as vesicular stomatitis virus. In contrast, we found no change in infectivity for Coxsackievirus B3, a non-enveloped virus. Derivatives of curcumin also exhibited antiviral activity against enveloped viruses. Further examination revealed that curcumin interfered with the binding of the enveloped viruses to cells in a dose-dependent manner, though the integrity of the viral RNA was maintained. Together, these results expand the family of viruses sensitive to curcumin and provide a mechanism of action for curcumin's effect on these enveloped viruses.
The ability of curcumin to prevent viral replication strongly suggests that this molecule and its derivatives may hold promise for the development of broad-range antivirals. Curcumin in the human diet, further, could provide a simple means to prevent infection by enveloped viruses.
Keywords: Curcumin Enveloped virus Viral binding
Curcumin inhibits Zika and chikungunya virus infection by inhibiting cell binding - Bryan C. Mounce, Teresa Cesaro, Lucia Carrau, Thomas Vallet, Marco Vignuzzi - Antiviral Research 142 (2017)
Curcuma longa extract improves serum infammatory markers and mental health
This study examined the effects of C. longa extract in healthy overweight subjects. The supplementation induced a reduction in body weight and BMI, as in CRP. The supplemented group has also an improvement in the mental health and anger-hostility score . Those beneficial effects on mood in overweight subjects are probably related to a reduction in body weight and inflammation.
Abstract Background: The dietary spice Curcuma longa, also known as turmeric, has various biological effects. Both a water extract and a supercritical carbon dioxide extract of C. longa showed anti-inflammatory activities in animal studies. However, the anti-inflammatory effect in humans of a mixture of these two C. longa extracts (CLE) is poorly understood. Therefore, we investigated the effect of CLE containing anti-inflammatory turmeronols on chronic inflammation and general health.
Methods: We performed a randomized, double-blind, placebo-controlled study in healthy subjects aged 50 to 69 years with overweight. Participants took two capsules containing CLE (CLE group, n = 45) or two placebo capsules (placebo group, n = 45) daily for 12 weeks, and serum inflammatory markers were measured. Participants also completed two questionnaires: the Medical Outcomes Study (MOS) 36-Item Short-Form Health Survey (SF-36) and the Profile of Mood States (POMS) scale. Treatment effects were analyzed by two way analysis of variance followed by a t test (significance level, p max 0.05).
Results: After the intervention, the CLE group had a significantly lower body weight (p max 0.05) and body mass index (p max 0.05) than the placebo group and significantly lower serum levels of C-reactive protein (p max 0.05) and complement component 3 (p max 0.05). In addition, the CLE group showed significant improvement of the MOS SF-36 mental health score (p max 0.05) and POMS anger-hostility score (p max 0.05).
Conclusion: CLE may ameliorate chronic low-grade inflammation and thus help to improve mental health and mood disturbance.
Discussion : Compared with the placebo group, body weight, BMI, and serum levels of CRP and C3 were significantly lower in the CLE group. In addition, the CLE group showed a significant improvement in the SF-36 subscale score for mental health and the POMS score for anger and hostility. These results suggest that intake of a mixture of a hot water extract and supercritical carbon dioxide extract of C. longa may have the potential to improve mental health and negative mood state by reducing chronic low-grade inflammation.
Curcuma longa extract improves serum inflammatory markers and mental health in healthy participants who are overweight: a randomized, double-blind, placebo-controlled trial Ryusei Uchio , Kengo Kawasaki, Chinatsu Okuda‑Hanafusa, Ryosuke Saji, Koutarou Muroyama, Shinji Murosaki, Yoshihiro Yamamoto and Yoshitaka Hirose
Curcumin and Pomegranate to a comprehensive exercise training plan
Combined supplementation with optimized curcumin and pomegranate extract may be useful as part of a comprehensive plan designed to mitigate post-exercise inflammation/injury and improve subsequent recovery between sessions.
ABSTRACT : Endurance running training can lead to gradual accumulation of inflammation and soreness ultimately resulting in overuse injuries. Management of soreness and inflammation with pharmaceuticals (i.e. non-prescription pain relievers) during long-term training is not a suitable solution due to known side effects (e.g. gastrointestinal complications, etc.). Dietary polyphenols (i.e. curcumin, pomegranate, etc.) have been purported to reduce inflammation and muscle sore-ness, without these negative side effects making them ideal for use in an exercise model. The purpose of the present feasibility study was to explore the combined effect of optimized curcumin and pomegranate extract supplementation prior to (PRE) and after (4H and 24H) an organized half-marathon race on blood inflammatory proteins and inflammation-associated RNA. Daily supplementation (1000 mg/d) started 26 days before a half-marathon which doubled on days 27-31. Data were analyzed with R software and Welch t-test, significance set at p max 0.05. At both 4H and 24H, supplementation was associated with alterations in protein (IL-10, IL-13, IL-4, ITAC, MIP-1alpha, MIP-3alpha, BDNF, sIL-2Ralpha, and TNF-alpha; p max 0.05) and RNA (CCL22, GUSB, IL-6, LINC00305, NKILA, PTGES, THRIL, TRAF6, ARG2, CD1A, CD55, CFI, CSF2, CXC3CL1, CX3CR1, EDNRB, GATA3, LILRB5, THY1, CD3D, MRC1, GPR183, HAMP, MBL2, CASP3, B2M, KLRF2, PDCD1LG2, IL-10, PTGS2, TLR2, IL-6R, IL-8, IL-7R, MASP1, MYD88, TNFRSF1B, TNFRSF1A, and TIRAP; p max 0.05) biomarkers com-pared to control. Pathway classification of these biomarkers indicated supplementation may be associated with a more favorable muscle recovery profile. Our findings support the notion that combined cur-cumin and pomegranate supplementation may represent a useful addition to a comprehensive exercise training plan.
Study for Curcumin + Pomegranate
Conclusion : Our findings support the notion that combined curcumin and pomegranate supplementation may represent a useful addition to a comprehensive exercise training plan. In conclusion, it is well documented that reduced post-exercise inflammation is associated with a faster return to normal function in activities of daily living or training The key findings of the present study when subjects were supplemented is consistent with previously reported reductions in post-exercise inflammation with curcumin alone Additionally, previous research with resistance training has shown an improvement in muscle damage with the consumption of pomegranate juice that is in line with the results of the current study it is reasonable to speculate that combined supplementation with optimized curcumin and pomegranate extract may be useful as part of a comprehensive plan designed to mitigate post-exercise inflammation/injury and improve subsequent recovery between sessions.
Additional research in this area of study is warranted to further characterize additional supplementation strategies (i.e. flexible dosing, short-term dosing, etc.) and methods for incorporating combined curcumin and pomegranate supplementation into individualized training plans.
Alterations in Systemic Inflammatory Response Following a Half-Marathon Race with a Combined Curcumin and Pomegranate Supplement: A Feasibility Study - Elizabeth A. Tanner , Melody A. Gary , Asheal A. Davis , Stephan Michalik & Brian K. McFarlin
Inhibition of dengue virus by curcuminoids
We conclude that curcuminoids exhibit their anti-viral activities through a variety of ways on the host cells, but with modest effect in DENV protease. Modulation of host actin and lipids may be involved in regulating the viral binding and entry.
The dengue virus is considered to be a globally important human pathogen prevalent in tropical and subtropical regions of the world. According to a recent estimate, the disease burden due to DENV infections is ∼390 million infections per year globally in ∼100 countries including the southern US, Puerto Rico and Hawaii, resulting in nearly ∼25,000 deaths mostly among children. Despite the significant morbidity and mortality that results from DENV infections, there is currently no effective chemotherapeutic treatment for DENV infections. We identified curcumin as an inhibitor of DENV2 NS2B/NS3protease in a previous high-throughput screening (HTS) campaign. We synthesized four analogues of curcumin (curcuminoids) and tested the in vitro protease inhibition activity and inhibition of replication by cell-based assays. The results revealed that curcumin is a weak inhibitor of the viral protease. However, the analogues exhibited more potent inhibition of DENV infectivity in plaque assays suggesting that the cellular pathway(s) required for viral replication and/or assembly are targeted by these compounds. Further analysis shows that inhibition of genes involved in lipid biosynthesis, and of actin polymerization by curcuminoids, are likely to be involved as their mode of action in DENV2-infected cells. Three of the curcumin derivatives possess good selectivity indices (SI) ( min 10) when compared to the parent curcumin.
Conclusion : We conclude that curcuminoids exhibit their anti-viral activities through a variety of ways on the host cells, but with modest effect in DENV protease. Modulation of host actin and lipids may be involved in regulating the viral binding and entry. Recent studies on DENV mouse models indicated that curcumin treatment reduced the DENV viremia effectively (Ichsyani et al., 2017) indicating that these analogues might be promising in antiviral therapy against DENV.
Inhibition of dengue virus by curcuminoids - Anuradha Balasubramanian, Rajendra Pilankatta, Tadahisa Teramoto, Ayyiliath M. Sajith, Evaristus Nwulia, Amol Kulkarni, Radhakrishnan Padmanabhan - Antiviral Research 162 (2019) 71–78
Curcumin against hepatitis C virus infection
Curcumin is (also) shown to inhibit the direct cell-to-cell transmission of virions, whereby they traffic in a stealthy manner protected from neutralising antibodies. Curcumin is inexpensive, efficiently blocks HCV entry into hepatocytes,
Infection with the HCV is one of the major causes of chronic liver disease with an estimated 184 million persons worldwide positive for HCV antibodies and 4 million newly infected each year. The situation is worrying in emerging countries of Central and Southeast Asia, North Africa and Middle East with seroprevalence around 3%–5%. Central Africa and Egypt remain regions of very high endemicity with a 25% prevalence in the latter. Hepatitis C is therefore a global health problem with striking inequalities in the access to healthcare and implementation of treatments between world regions.
(...) Several aspects of this study deserve attention. Curcumin is inexpensive, efficiently blocks HCVentry into hepatocytes, exerts pan-genotypic antiviral activity and can be orally administered and preliminary data from Anggakusuma et al seem to indicate a high barrier to resistance. Recent clinical trials have pointed its high tolerance and favourable safety profile in healthy subjects.10 Curcumin is combinable with existing therapies,9 and may be judiciously combined to per os IFN-free therapies currently under trials, based upon novel pan-genotypic DAA. (...)
Comments for Curcumin
Curcumin against hepatitis C virus infection: spicing up antiviral therapies with ‘nutraceuticals’ - Eve-Isabelle Pécheur, Gut July 2014 Vol 63 No 7
Curcumin on Diabetes Mellitus - Systematic Review
Curcumin is a natural anti-inflammatory and anti-diabetic agent representing a safe and low-cost alternative for this condition’s therapeutic approach. Anti-diabetic activity might be due to its capacity to suppress oxidative stress and inflammatory process. Curcumin also significantly reduces fasting blood glucose, glycated hemoglobin, and body mass index.
Abstract : Diabetes mellitus (DM) is an ensemble of metabolic conditions that have reached pandemic proportions worldwide. Pathology’s multifactorial nature makes patient management, including lifelong drug therapy and lifestyle modification, extremely challenging. Currently, there is growing evidence about the effectiveness of using herbal supplements in preventing and controlling DM. Curcumin is a bioactive component found Curcuma longa, which exhibits several physiological and pharmacological properties such as antioxidant, anti-inflammatory, anticancer, neuroprotective, and anti-diabetic activities. For these reasons, our objective is to systematically review the effects of Curcuma longa or curcumin on DM. Databases such as PUBMED and EMBASE were searched, and the final selection included sixteen studies that fulfilled the inclusion criteria. The results showed that curcumin’s anti-diabetic activity might be due to its capacity to suppress oxidative stress and inflammatory process. Also, it significantly reduces fasting blood glucose, glycated hemoglobin, and body mass index. Nanocurcumin is also associated with a significant reduction in triglycerides, VLDL-c, total cholesterol, LDL-c, HDL-c, serum C reactive protein, and plasma malonaldehyde. Therefore, it can be considered in the therapeutic approach of patients with DM.
Conclusion : T2DM has a multifactorial pathology and affects thousands of people worldwide. Its treatment consists of lifestyle changes, diet, physical activity, and therapies with medications for the rest of life. Curcumin is a natural anti-inflammatory and anti-diabetic agent representing a safe and low-cost alternative for this condition’s therapeutic approach, although it is still necessary to know its effective dose. We suggest that more robust and rigorous randomized controlled clinical trials are carried out to establish the role of curcumin in the therapeutics of T2DM.
Keywords: Curcuma longa, curcumin, curcuminoids, diabetes, type 2 diabetes mellitus
The Effects of Curcumin on Diabetes Mellitus: A Systematic Review, Ledyane Taynara Marton, Laís Maria Pescinini-E-Salzedas, Maria Eduarda Côrtes Camargo, Sandra M Barbalho, Jesselina F Dos Santos Haber, Renata Vargas Sinatora, Claudia Rucco Penteado Detregiachi, Raul J S Girio, Daniela Vieira Buchaim, Patricia Cincotto Dos Santos Bueno, Front Endocrinol (Lausanne), 2021 May 3
Curcumin inhibits cancer stem cell phenotypes in ex vivo models of colorectal liver metastase
Curcumin may provide added benefit in subsets of patients when administered with FOLFOX, and is a well-tolerated chemotherapy adjunct.
In vitro and pre-clinical studies have suggested that addition of the diet-derived agent curcumin may provide a suitable adjunct to enhance efficacy of chemotherapy in models of colorectal cancer. However, the majority of evidence for this currently derives from established cell lines.
Here, we utilised patient-derived colorectal liver metastases (CRLM) to assess whether curcumin may provide added benefit over 5-fluorouracil (5-FU) and oxaliplatin (FOLFOX) in cancer stem cell (CSC) models.
Combination of curcumin with FOLFOX chemotherapy was then assessed clinically in a phase I dose escalation study. Curcumin alone and in combination significantly reduced spheroid number in CRLM CSC models, and decreased the number of cells with high aldehyde dehydrogenase activity (ALDHhigh/ CD133−). Addition of curcumin to oxaliplatin/5-FU enhanced anti-proliferative and pro-apoptotic effects in a proportion of patient-derived explants, whilst reducing expression of stem cell-associated markers ALDH and CD133. The phase I dose escalation study revealed curcumin to be a safe and tolerable adjunct to FOLFOX chemotherapy in patients with CRLM (n = 12) at doses up to 2 grams daily.
Curcumin may provide added benefit in subsets of patients when administered with FOLFOX, and is a well-tolerated chemotherapy adjunct.
Curcumin inhibits cancer stem cell phenotypes in ex vivo models of colorectal liver metastases, and is clinically safe and tolerable in combination with FOLFOX chemotherapy Cancer Letters 364 (2015) 135–141
Efficacy and safety of Curcuma longa Extract on osteoarthritis (systematic review)
Based on the compilation of 15 randomized and controlled trials, this meta-analysis confirms the beneficial effects of Curcuma longa Extract and curcumin on joint health
Objective: To assess the efficacy and safety of Curcuma longa Extract and curcumin supplements on osteoarthritis (OA).
Methods: The databases such as Pubmed and Cochrane Library were searched to collect the article about Curcuma longa Extract and curcumin in the treatment of OA. Then, randomized controlled trials (RCTs) were selected and their data was extracted. Finally, the RevMan5.3 was utilized for risk of bias assessment and meta-analysis, the STATA15.0 were utilized for publication bias assessment, and GRADE tool were used for the evidence quality assessment of primary outcomes.
Results: A total of 15 RCTs involving 1621 participants were included. (1) Compared with placebo, Curcuma longa Extract and curcumin (C.) can decrease the VAS and WOMAC score-pain, the WOMAC score-function and the WOMAC score-stiffness. In terms of adverse events, Curcuma longa Extract and curcumin are comparable to those of placebo. (2) Compared with NSAIDs, Curcuma longa Extract and curcumin have similar effects on joint pain, function and stiffness. The incidence of adverse events in Curcuma longa Extract and curcumin was lower. (3) Compared with the NSAIDs group, C.+NSAIDs can also decrease the VAS and WOMAC score-pain, the WOMAC score-function and the WOMAC score-stiffness. In terms of adverse events, the addition of Curcuma longa Extract and curcumin to NSAIDs did not increase adverse events.
So, Results showed significant effects of supplementations on the VAS and WOMAC score-pain, the WOMAC score-function and the WOMAC score-stiffness.
Conclusion: Curcuma longa Extract and curcumin may be a safer and effective supplement for OA patients. It is recommended to use Curcuma longa Extract and curcumin supplement for OA patients for more than 12 weeks.
Keywords: Curcuma longa Extract; Curcumin; Meta-analysis; Osteoarthritis; Systematic review.
The efficacy and safety of Curcuma longa Extract and curcumin supplements on osteoarthritis: a systematic review and meta-analysis, Liuting Zeng, Kailin Yang, Wensa Hao, Ganpeng Yu, Hua Chen, Biosci Rep, 2021 May 21
Inhibition of curcumin on influenza A virus infection and influenzal pneumonia
In conclusion, besides directly inactivating IAV and inhibiting IAV adsorption, curcumin can activate Nrf2 signal, stimulates the production of many antioxidases, suppresses IAV-mediated oxidative stress and further indirectly inhibits IAV-induced activation of TLR2/4, p38/JNK MAPK and NF-κB pathways, which may inhibit both IAV-mediated inflammation and IAV replication.
Oxidative stress, Nrf2-HO-1 and TLR-MAPK/NF-κB signaling pathways have been proved to be involved in influenza A virus (IAV) replication and influenzal pneumonia. In the previous studies, we have performed several high-throughput drug screenings based on the TLR pathways. In the present study, through plaque inhibition test, luciferase reporter assay, TCID50, qRT-PCR, western blotting, ELISA and siRNA assays, we investigated the effect and mechanism of action of curcumin against IAV infection in vitro and in vivo. The results showed that curcumin could directly inactivate IAV, blocked IAV adsorption and inhibited IAV proliferation. As for the underlying mechanisms, we found that curcumin could significantly inhibit IAV-induced oxidative stress, increased Nrf2, HO-1, NQO1, GSTA3 and IFN-β production, and suppressed IAV-induced activation of TLR2/4/7, Akt, p38/JNK MAPK and NF-κB pathways. Suppression of Nrf2 via siRNA significantly abolished the stimulatory effect of curcumin on HO-1, NQO1, GSTA3 and IFN-β production and meanwhile blocked the inhibitory effect of curcumin on IAV M2 production. Oxidant H2O2 and TLR2/4, p38/JNK and NF-κB agonists could significantly antagonize the anti-IAV activity of curcumin in vitro. Additionally, curcumin significantly increased the survival rate of mice, reduced lung index, inflammatory cytokines and lung IAV titer, and finally improved pulmonary histopathological changes after IAV infection. In conclusion, curcumin can directly inactivate IAV, inhibits IAV adsorption and replication; and its inhibition on IAV replication may be via activating Nrf2 signal and inhibiting IAV-induced activation of TLR2/4, p38/JNK MAPK and NF-κB pathways.
In conclusion, besides directly inactivating IAV and inhibiting IAV adsorption, curcumin can activate Nrf2 signal, stimulates the production of many antioxidases, such as CAT, SOD, GSH-Px, HO-1, NQO1 and GSTA3, suppresses IAV-mediated oxidative stress and further indirectly inhibits IAV-induced activation of TLR2/4, p38/JNK MAPK and NF-κB pathways, which may inhibit both IAV-mediated inflammation and IAV replication. Meanwhile, activation of Nrf2-HO-1 pathway can increase the production of IFN-β which may also further suppress IAV replication. Finally curcumin improves IAV-induced ALI/ARDS (Fig. 8). Additionally, curcumin has been used as a coloring agent and spice in foods for thousands of years, it possesses very low cytotoxicity, this may make curcumin to be utilized to treat IAV infection in the clinic directly.
Inhibition of curcumin on influenza A virus infection and influenzal pneumonia via oxidative stress, TLR2/4, p38/JNK MAPK and NF-κB pathways - Jianping Dai, Liming Gu, Yun Su, Qianwen Wang, Ying Zhao, Xiaoxua Chen, Huixiong Deng, Weizhong Li, Gefei Wang, Kangsheng Li - International Immunopharmacology 54 (2018) 177–187
Several Member States in EU are reworking the list in the Novel Food catalogue. Even if we - at BECARRE Natural - believe that the situation sometimes goes beyond the initial need of Novel Food – to be able to demonstrate the food safety of a plant or a plant extract – it is clear that this creates questions for our market.
Novel food : The regulation authorizing the tetrahydrocurcuminoids C3 Reduct® has been published today, with validation of the 5 years protection
Curcumin C3 Reduct® is the hydrogenated derivative of the natural curcuminoids from Curcumin C3 Complex®, allowing to bring directly the active metabolites. After the positive opinion by EFSA on very last end of December, the authorization has just been published today in the official journal. Our C3 Reduct® by Sabinsa can so be lawfully on the market within 20 days.
As the main Sponsor, Becarre Natural is waiting for you at Nutriform Business Days, 3 days of sharing and discussions, inspiring conferences and round tables dedicated to international news on the dietary supplements market, scientific and marketing solutions to develop your business.
Research supports the benefits of Sabinsa's C3 Reduct and its tetrahydrocurcuminoids in supporting human health.
Sabinsa has obtained Novel Food approval from EFSA for C3® Reduct, the curcuma extract with the curcuminoid metabolites Tetrahydrocurcuminoids (THCs).
Pourquoi un dossier Novel Food ? Retour sur l'accord par l'EFSA donné aux tétrahydrocurcuminoïdes du curcuma. Quel impact pour le secteur de la nutraceutique ?
New Research Published on Sabinsa’s Curcumin C3 Reduct® Supports Efficacy as an Oral Care Ingredient
New research has recently been published that builds upon evidence from a previous trial investigating the potential of Sabinsa’s Curcumin C3 Reduct® ingredient in oral care applications. Tetrahydrocurcuminoids (THCs) are among the major active metabolites formed on oral curcuminoids ingestion. The myriad useful pharmacological properties of THCs have rendered them so unique that Sabinsa markets them as Curcumin C3 Reduct®, a self-affirmed GRAS ingredient entirely composed of these reductive metabolites.
Are you interested in our solutions and want to know more?
Becarre Natural represents, distributes and develops natural actives extracts from plants for nutrition health and cosmeceutical.Contact us